Poor efficacy clouds prospects for the company's "improved" Yervoy.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.